<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04488770</url>
  </required_header>
  <id_info>
    <org_study_id>212148</org_study_id>
    <secondary_id>2020-000680-23</secondary_id>
    <nct_id>NCT04488770</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.</brief_title>
  <official_title>A Double-Blind Randomized, Placebo-Controlled, Single and Repeated Oral Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Effect) of GSK3882347 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled,&#xD;
      first time in human (FTIH) study, that includes both single-ascending and multiple-ascending&#xD;
      dose phase to assess the safety, tolerability, and pharmacokinetics (PK) of GSK3882347 in&#xD;
      healthy adult men and Woman of Non Childbearing Potential (WONCBP). Part 1 will be the single&#xD;
      ascending dose (SAD) phase and Part 2 will be the multiple ascending dose (MAD) phase. Each&#xD;
      participant in the SAD cohort will receive a single dose of GSK3882347 or placebo (PBO) in&#xD;
      3:1 ratio and in Part 2 (MAD), participants will be randomized in a 4:1 ratio to receive&#xD;
      active treatment and placebo. Part 1 will consist of two cohorts with a maximum of&#xD;
      four-period for each cohort, the food effect evaluation will be conducted in last period&#xD;
      (Period 4) in only one of the cohorts based on the observed human pharmacokinetics (PK). Part&#xD;
      2 will consist of maximum of four cohorts for each of the MAD dose or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Actual">May 14, 2021</completion_date>
  <primary_completion_date type="Actual">May 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part 1 will consist of two cohorts (Cohorts 1 and 2) with a maximum of four periods in a cross-over design conducted in two separate cohorts. Part 2 consists of a maximum of four ascending repeat-dose cohorts (Cohorts 3 to 6) for which participants, will receive a single oral dose of GSK3882347 or placebo for 7 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind study with participants and the site staff blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (greater than or equal to [&gt;=]5 percent [%]) non-serious AEs is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Non-serious AEs and SAEs</measure>
    <time_frame>Up to 26 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (&gt;=5%) non-serious AEs is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Treatment Related AEs</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Treatment Related AEs</measure>
    <time_frame>Up to 26 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst-case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter(g/L) for hemoglobin,&lt;3 or &gt;20 x10^9 cells per liter(cells/L) for leukocytes,&lt;0.8 x10^9 cells/L for lymphocytes,&lt;1.5 x10^9 cells/L for neutrophils and &lt;100 or &gt;550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(for example[e.g.],High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst-case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Up to 26 days</time_frame>
    <description>Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter(g/L) for hemoglobin,&lt;3 or &gt;20 x10^9 cells per liter(cells/L) for leukocytes,&lt;0.8 x10^9 cells/L for lymphocytes,&lt;1.5 x10^9 cells/L for neutrophils and &lt;100 or &gt;550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Blood samples were collected to analyze PCI ranges: &gt;=2 times Upper limit of Normal(ULN) Units per Liter(U/L) for Alanine aminotransferase(ALT),&gt;=2 times ULN U/L for alkaline phosphatase(ALP), &gt;=2 times ULN U/L for aspartate aminotransferase(AST),&gt;=1.5 times ULN micromoles/L for bilirubin,&lt;2 or &gt;2.75 millimoles/L (mmol/L) for calcium,&lt;3 or &gt;9 mmol/L for glucose,&lt;3 or &gt;5.5 mmol/L for potassium and &lt;130 or &gt;150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Up to 26 days</time_frame>
    <description>Blood samples were collected to analyze PCI ranges: &gt;=2 times ULN U/L for Alanine aminotransferase(ALT),&gt;=2 times ULN U/L for alkaline phosphatase(ALP), &gt;=2 times ULN U/L for aspartate aminotransferase(AST),&gt;=1.5 times ULN micromoles/L for bilirubin,&lt;2 or &gt;2.75 mmol/L for calcium,&lt;3 or &gt;9 mmol/L for glucose,&lt;3 or &gt;5.5 mmol/L for potassium and &lt;130 or &gt;150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline</measure>
    <time_frame>Up to 26 days</time_frame>
    <description>Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner (proportional concentrations in urine samples), and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein. 'No change/decreased' indicates no change from Baseline results or decreased in results from Baseline including change in negative results. 'Increase to positive' indicates increase in result from Baseline. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were &lt;85 (Low), 85-160 (Normal) and &gt;160 (High) for SBP; &lt;45 (Low), 45-100 (Normal), &gt;100 (High) for DBP; &lt;40 (Low), 40-110 (Normal), &gt;110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline</measure>
    <time_frame>Up to 26 days</time_frame>
    <description>Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were &lt;85 (Low), 85-160 (Normal) and &gt;160 (High) for SBP; &lt;45 (Low), 45-100 (Normal), &gt;100 (High) for DBP; &lt;40 (Low), 40-110 (Normal), &gt;110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Results Post Baseline Relative to Baseline</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Abnormal ECG Results Post Baseline Relative to Baseline</measure>
    <time_frame>Up to 26 days</time_frame>
    <description>A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-t]) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC[0-infinity]) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time to Cmax (Tmax) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lag Time for Absorption (Tlag) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Terminal Elimination Half-life (T1/2) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve Over the Dosing Interval Tau (AUC[0-tau]) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Plasma Concentrations Over the Dosing Interval (Ctau) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Urine Concentration Between 22-24 Hours (C22-24) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Day 1: 22-24 hours post-dose in each treatment period</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Urine Concentration Between 22-24 Hours (C22-24) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Day 1 and Day 7: 22-24 hours post-dose</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Single Dose Administration of GSK3882347</measure>
    <time_frame>At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Days 1 and 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347</measure>
    <time_frame>At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100 percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Day 1 and Day 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Renal Clearance of Drug (CLr) After Single Dose Administration of GSK3882347</measure>
    <time_frame>At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Renal Clearance of Drug (CLr) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Day 1 and Day 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose</time_frame>
    <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Plasma Concentrations at 12 Hours (C12) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent Oral Clearance (CL/F) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent Volume of Distribution After Oral Administration (Vz/F) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Mean Residence Time (MRT) After Single Dose Administration of GSK3882347</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Plasma Concentrations at 12 Hours (C12) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using AUC(0-infinity) After Single Dose Administration of GSK3882347 Under Fasted Condition</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using Cmax After Single Dose Administration of GSK3882347 Under Fasted Condition</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using AUC(0-tau) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using Cmax After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Observed Accumulation Ratio (Ro) Using AUC(0-tau) After Repeat Dose Administration of GSK3882347</measure>
    <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) at Day 7 divided by AUC(0-tau) at Day 1 for GSK3882347. Mixed effect model was used to assess accumulation ratio for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time Invariance of GSK3882347</measure>
    <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for the analysis of time invariance. Time invariance was calculated as AUC(0-tau) at Day 7 divided by AUC(0-infinity) at Day 1 for GSK3882347. Mixed effect ANOVA model was used to assess time invariance for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Pre-dose Plasma Concentrations After Repeat Dose Administration of GSK3882347 From Days 3 to 7</measure>
    <time_frame>Days 3, 4, 5, 6 and 7: Pre-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC [0-t]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC [0-infinity]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tlag After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</measure>
    <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Part 1 (SAD) Cohort 1:Participants receiving GSK3882347</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (SAD),Cohort 1:Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (SAD),Cohort 2: Participants receiving GSK3882347</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this single ascending dose phase, participants will receive GSK3882347 500 mg, 15 mg and 900 mg orally on Day 1 of period 1, 3 and 2 respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (SAD),Cohort 2: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 3 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this multiple ascending dose phase, participants will receive GSK3882347 50 mg orally on Day 1 to Day 7 of the study. The dose to be administered may be changed based on clinical safety, tolerability and PK findings in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (MAD),Cohort 3: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK3882347 150 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (MAD),Cohort 4: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK3882347 500 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (MAD),Cohort 5: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK3882347 900 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 6 will be based on PK/PD results from preceding dosing cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2(MAD),Cohort 6: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3882347</intervention_name>
    <description>Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.</description>
    <arm_group_label>Part 1 (SAD) Cohort 1:Participants receiving GSK3882347</arm_group_label>
    <arm_group_label>Part 1 (SAD),Cohort 2: Participants receiving GSK3882347</arm_group_label>
    <arm_group_label>Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg</arm_group_label>
    <arm_group_label>Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg</arm_group_label>
    <arm_group_label>Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg</arm_group_label>
    <arm_group_label>Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching strength placebo capsules will be provided</description>
    <arm_group_label>Part 1 (SAD),Cohort 1:Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 1 (SAD),Cohort 2: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 2 (MAD),Cohort 3: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 2 (MAD),Cohort 4: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 2 (MAD),Cohort 5: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 2(MAD),Cohort 6: Participants receiving Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 50 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, and cardiac monitoring. A&#xD;
             participant with a clinical abnormality or laboratory parameter(s) not specifically&#xD;
             listed in the exclusion or exclusion criteria that is outside the reference range for&#xD;
             the population being studied may be included only if the investigator, in consultation&#xD;
             with the Medical Monitor (if required), agree and document that the finding is&#xD;
             unlikely to introduce additional risk factors and will not interfere with the study&#xD;
             procedures.&#xD;
&#xD;
          -  Participants with Body weight at least 50.0 kilograms (kg) (110 pound [lbs]) for males&#xD;
             and 45.0 kg (99 lbs.) for females; and body mass index (BMI) within the range 18.5 -&#xD;
             32.0 kilograms per meter square (kg/m^2) (inclusive).&#xD;
&#xD;
          -  Male and female participants; a female participant is eligible to participate if she&#xD;
             is of WONCBP; Male participants are eligible to participate if they agree to the&#xD;
             following during the intervention period for at least five days, corresponding to time&#xD;
             needed to eliminate study intervention(s) (e.g. 5 terminal half-lives) after the last&#xD;
             dose of study intervention), refrain from donating sperm, be abstinent from&#xD;
             heterosexual or homosexual intercourse as their preferred and usual lifestyle&#xD;
             (abstinent on a long term and persistent basis) and agree to remain abstinent; must&#xD;
             agree to use contraception/barrier, agree to use a male condom.&#xD;
&#xD;
          -  Capable of giving signed informed consent as described in which includes compliance&#xD;
             with the requirements and restrictions listed in the informed consent form (ICF) and&#xD;
             in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with history or presence of cardiovascular, respiratory, hepatic,&#xD;
             urological, gastrointestinal, endocrine, hematological, or neurological disorders&#xD;
             capable of significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study intervention; or interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Alanine transaminase (ALT) greater than 1.5 times upper limit of normal (ULN).&#xD;
&#xD;
          -  Bilirubin greater than 1.5 times ULN (isolated bilirubin greater than1.5 times ULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin is less than 35%)&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
             (except for Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Medical history of cardiac arrhythmias or cardiac disease or a family or personal&#xD;
             history of long QT syndrome.&#xD;
&#xD;
          -  Male participants with heart rate of less than 45 or greater than 100 beats per minute&#xD;
             (bpm), females with less than 50 or greater than 100 bpm.&#xD;
&#xD;
          -  Participants with PR interval less than 120 or greater than 220 milliseconds (msec);&#xD;
             QRS duration less than 70 msec or greater than 120 msec; QTcF interval greater than&#xD;
             450 msec.&#xD;
&#xD;
          -  Evidence of previous myocardial infarction on ECG (does not include ST segment changes&#xD;
             associated with re-polarization).&#xD;
&#xD;
          -  Any conduction abnormality (including but not specific to left or right complete&#xD;
             bundle branch block, atrioventricular (AV) block [2nd degree or higher],&#xD;
             Wolff-Parkinson-White [WPW] syndrome).&#xD;
&#xD;
          -  Sinus Pauses greater than 3 seconds.&#xD;
&#xD;
          -  Any significant arrhythmia which, in the opinion of the Investigator or GSK Medical&#xD;
             Monitor, will interfere with the safety for the individual participant.&#xD;
&#xD;
          -  Non-sustained or sustained ventricular tachycardia (3 consecutive ventricular ectopic&#xD;
             beats).&#xD;
&#xD;
          -  Current or history of renal disease, or estimated creatinine clearance &lt;90 milliliter&#xD;
             (mL)/minute/1.73meter^2 or serum creatinine greater than ULN at screening.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) before the first dose of study intervention, unless in the opinion of the&#xD;
             Investigator and the GSK medical monitor, the medication will not interfere with the&#xD;
             study procedures or compromise participant safety.&#xD;
&#xD;
          -  Use of a systemic antimicrobial within 30 days of screening.&#xD;
&#xD;
          -  Participation in the study would result in loss of blood or blood products in excess&#xD;
             of 500 mL within 56 days.&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Current enrolment or past participation within the last 30 days before signing of&#xD;
             consent in any other clinical study involving an investigational study intervention or&#xD;
             any other type of medical research.&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) antibody test.&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior&#xD;
             to first dose of study intervention.&#xD;
&#xD;
          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to&#xD;
             first dose of study intervention.&#xD;
&#xD;
          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3&#xD;
             months prior to first dose of study intervention.&#xD;
&#xD;
          -  Positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  Any history of substance abuse or a positive test for drugs of abuse at screening or&#xD;
             admission.&#xD;
&#xD;
          -  A positive highly sensitive pregnancy test (urine or serum as required by local&#xD;
             regulations) at screening.&#xD;
&#xD;
          -  A positive laboratory confirmation of COVID-19 infection, or high clinical index of&#xD;
             suspicion for COVID-19.&#xD;
&#xD;
          -  Part 1 (Food Effect): Participant must have no dietary restrictions (e.g., lactose&#xD;
             intolerance) or inability to eat a high fat meal.&#xD;
&#xD;
          -  Regular alcohol consumption within 6 months prior to the study defined as: An average&#xD;
             weekly intake of greater than 21 units for males or greater than 14 units for females.&#xD;
             One unit is equivalent to approximately (250 mL) of beer, (100 mL) of wine or (35 mL)&#xD;
             measure of spirits.&#xD;
&#xD;
          -  Positive smoke breathalyzer indicative of smoking history at screening and each&#xD;
             in-house admission to the clinical research unit or regular use of tobacco- or&#xD;
             nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Hypersensitivity to any of the study interventions, or components thereof, or drug or&#xD;
             other allergy that, in the opinion of the investigator or medical monitor,&#xD;
             contraindicates participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <results_first_submitted>May 10, 2022</results_first_submitted>
  <results_first_submitted_qc>May 10, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2023</results_first_posted>
  <last_update_submitted>May 10, 2022</last_update_submitted>
  <last_update_submitted_qc>May 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAD</keyword>
  <keyword>MAD</keyword>
  <keyword>FTIH</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Urinary Tract Infections</keyword>
  <keyword>GSK3882347</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT04488770/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT04488770/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a 2-part, first-time-in-human (FTIH), dose-escalation, placebo (PBO)-controlled, single dose (SD) (Part 1) and repeat dose (RD) (Part 2) study to determine the safety, tolerability and pharmacokinetic (PK) profile of GSK3882347 in healthy participants. The study was conducted at a single center in the United Kingdom.</recruitment_details>
      <pre_assignment_details>A total of 61 participants (21 participants in Part 1 and 40 participants in Part 2) were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part1-Cohort1:GSK3882347 SD 50mg/SD 150mg/SD 250 mg/SD PBO</title>
          <description>Healthy participants in Part 1 Cohort 1 received a single dose (SD) of GSK3882347 50 milligrams (mg) on Day 1 in treatment Period 1, followed by a SD of GSK3882347 150 mg on Day 1 in treatment Period 2, followed by a SD of GSK3882347 250 mg on Day 1 in treatment Period 3, further followed by a SD of Placebo (PBO) on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="P2">
          <title>Part1-Cohort1:GSK3882347 SD 50mg/SD 150mg/SD PBO/SD 250mg Fed</title>
          <description>Healthy participants in Part 1 Cohort 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1, followed by a SD of GSK3882347 150 mg on Day 1 in treatment Period 2, followed by a SD of PBO on Day 1 in treatment Period 3, further followed by a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="P3">
          <title>Part1-Cohort1: GSK3882347 SD 50mg/SD PBO/SD 250mg/SD 250mg Fed</title>
          <description>Healthy participants in Part 1 Cohort 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1, followed by a SD of PBO on Day 1 in treatment Period 2, followed by a SD of GSK3882347 250 mg on Day 1 in treatment Period 3, further followed by a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="P4">
          <title>Part1-Cohort1:SD PBO/GSK3882347 SD 150mg/SD 250mg/SD 250mg Fed</title>
          <description>Healthy participants in Part 1 Cohort 1 received a SD of PBO on Day 1 in treatment Period 1, followed by a SD of GSK3882347 150 mg on Day 1 in treatment Period 2, followed by a SD of GSK3882347 250 mg on Day 1 in treatment Period 3, further followed by a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="P5">
          <title>Part 1-Cohort 2: SD PBO/GSK3882347 SD 900 mg/SD 15 mg</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of PBO on Day 1 in treatment Period 1, followed by a SD of GSK3882347 900 mg on Day 1 in treatment Period 2, further followed by a SD of GSK3882347 15 mg on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="P6">
          <title>Part 1-Cohort 2: GSK3882347 SD 500 mg/SD PBO/SD 15 mg</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1, followed by a SD of PBO on Day 1 in treatment Period 2, further followed by a SD of GSK3882347 15 mg on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="P7">
          <title>Part 1-Cohort 2: GSK3882347 SD 500 mg/SD 900 mg/SD PBO</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1, followed by a SD of GSK3882347 900 mg on Day 1 in treatment Period 2, further followed by a SD of PBO on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="P8">
          <title>Part 1-Cohort 2: GSK3882347 SD 500 mg/SD 900 mg/SD 15 mg</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1, followed by a SD of GSK3882347 900 mg on Day 1 in treatment Period 2, further followed by a SD of GSK3882347 15 mg on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="P9">
          <title>Part 2: Repeat Dose Placebo</title>
          <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
        </group>
        <group group_id="P10">
          <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
        </group>
        <group group_id="P11">
          <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
        </group>
        <group group_id="P12">
          <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
        </group>
        <group group_id="P13">
          <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1-Cohort 1: Period 1 (Up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1-Cohort 1: Period 2 (Up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2">New participant enrolled and dosed as a replacement of withdrawn participant</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1-Cohort 1: Period 3 (Up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1-Cohort 1: Period 4 (Up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">New participant enrolled and dosed as a replacement of withdrawn participant</participants>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1-Cohort 2: Period 1 (Up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1-Cohort 2: Period 2 (Up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2">New participant enrolled and dosed as a replacement of withdrawn participant</participants>
                <participants group_id="P7" count="2">New participant enrolled and dosed as a replacement of withdrawn participant</participants>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1-Cohort 2: Period 3 (Up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2">New participant enrolled and dosed as a replacement of withdrawn participant</participants>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 (Up to 26 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part1-Cohort1:GSK3882347 SD 50mg/SD 150mg/SD 250 mg/SD PBO</title>
          <description>Healthy participants in Part 1 Cohort 1 received a single dose (SD) of GSK3882347 50 milligrams (mg) on Day 1 in treatment Period 1, followed by a SD of GSK3882347 150 mg on Day 1 in treatment Period 2, followed by a SD of GSK3882347 250 mg on Day 1 in treatment Period 3, further followed by a SD of Placebo (PBO) on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="B2">
          <title>Part1-Cohort1:GSK3882347 SD 50mg/SD 150mg/SD PBO/SD 250mg Fed</title>
          <description>Healthy participants in Part 1 Cohort 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1, followed by a SD of GSK3882347 150 mg on Day 1 in treatment Period 2, followed by a SD of PBO on Day 1 in treatment Period 3, further followed by a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="B3">
          <title>Part1-Cohort1: GSK3882347 SD 50mg/SD PBO/SD 250mg/SD 250mg Fed</title>
          <description>Healthy participants in Part 1 Cohort 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1, followed by a SD of PBO on Day 1 in treatment Period 2, followed by a SD of GSK3882347 250 mg on Day 1 in treatment Period 3, further followed by a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="B4">
          <title>Part1-Cohort1:SD PBO/GSK3882347 SD 150mg/SD 250mg/SD 250mg Fed</title>
          <description>Healthy participants in Part 1 Cohort 1 received a SD of PBO on Day 1 in treatment Period 1, followed by a SD of GSK3882347 150 mg on Day 1 in treatment Period 2, followed by a SD of GSK3882347 250 mg on Day 1 in treatment Period 3, further followed by a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4. Cohort 1 was a 4-period cross-over.</description>
        </group>
        <group group_id="B5">
          <title>Part 1-Cohort 2: SD PBO/GSK3882347 SD 900 mg/SD 15 mg</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of PBO on Day 1 in treatment Period 1, followed by a SD of GSK3882347 900 mg on Day 1 in treatment Period 2, further followed by a SD of GSK3882347 15 mg on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="B6">
          <title>Part 1-Cohort 2: GSK3882347 SD 500 mg/SD PBO/SD 15 mg</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1, followed by a SD of PBO on Day 1 in treatment Period 2, further followed by a SD of GSK3882347 15 mg on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="B7">
          <title>Part 1-Cohort 2: GSK3882347 SD 500 mg/SD 900 mg/SD PBO</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1, followed by a SD of GSK3882347 900 mg on Day 1 in treatment Period 2, further followed by a SD of PBO on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="B8">
          <title>Part 1-Cohort 2: GSK3882347 SD 500 mg/SD 900 mg/SD 15 mg</title>
          <description>Healthy participants in Part 1 Cohort 2 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1, followed by a SD of GSK3882347 900 mg on Day 1 in treatment Period 2, further followed by a SD of GSK3882347 15 mg on Day 1 in treatment Period 3. Cohort 2 was a 3-period cross-over.</description>
        </group>
        <group group_id="B9">
          <title>Part 2: Repeat Dose Placebo</title>
          <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
        </group>
        <group group_id="B10">
          <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
        </group>
        <group group_id="B11">
          <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
        </group>
        <group group_id="B12">
          <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
        </group>
        <group group_id="B13">
          <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="8"/>
            <count group_id="B12" value="8"/>
            <count group_id="B13" value="8"/>
            <count group_id="B14" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian- South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White- White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (greater than or equal to [&gt;=]5 percent [%]) non-serious AEs is presented.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Safety Population comprised of all participants who received at least one dose of study intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose Placebo</title>
            <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (greater than or equal to [&gt;=]5 percent [%]) non-serious AEs is presented.</description>
          <population>Safety Population comprised of all participants who received at least one dose of study intervention.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Non-serious AEs and SAEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (&gt;=5%) non-serious AEs is presented.</description>
        <time_frame>Up to 26 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose Placebo</title>
            <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Non-serious AEs and SAEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (&gt;=5%) non-serious AEs is presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Treatment Related AEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose Placebo</title>
            <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Treatment Related AEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Treatment Related AEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.</description>
        <time_frame>Up to 26 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose Placebo</title>
            <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Treatment Related AEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst-case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter(g/L) for hemoglobin,&lt;3 or &gt;20 x10^9 cells per liter(cells/L) for leukocytes,&lt;0.8 x10^9 cells/L for lymphocytes,&lt;1.5 x10^9 cells/L for neutrophils and &lt;100 or &gt;550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(for example[e.g.],High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose Placebo</title>
            <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst-case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter(g/L) for hemoglobin,&lt;3 or &gt;20 x10^9 cells per liter(cells/L) for leukocytes,&lt;0.8 x10^9 cells/L for lymphocytes,&lt;1.5 x10^9 cells/L for neutrophils and &lt;100 or &gt;550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(for example[e.g.],High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst-case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter(g/L) for hemoglobin,&lt;3 or &gt;20 x10^9 cells per liter(cells/L) for leukocytes,&lt;0.8 x10^9 cells/L for lymphocytes,&lt;1.5 x10^9 cells/L for neutrophils and &lt;100 or &gt;550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
        <time_frame>Up to 26 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose Placebo</title>
            <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst-case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter(g/L) for hemoglobin,&lt;3 or &gt;20 x10^9 cells per liter(cells/L) for leukocytes,&lt;0.8 x10^9 cells/L for lymphocytes,&lt;1.5 x10^9 cells/L for neutrophils and &lt;100 or &gt;550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected to analyze PCI ranges: &gt;=2 times Upper limit of Normal(ULN) Units per Liter(U/L) for Alanine aminotransferase(ALT),&gt;=2 times ULN U/L for alkaline phosphatase(ALP), &gt;=2 times ULN U/L for aspartate aminotransferase(AST),&gt;=1.5 times ULN micromoles/L for bilirubin,&lt;2 or &gt;2.75 millimoles/L (mmol/L) for calcium,&lt;3 or &gt;9 mmol/L for glucose,&lt;3 or &gt;5.5 mmol/L for potassium and &lt;130 or &gt;150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose Placebo</title>
            <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected to analyze PCI ranges: &gt;=2 times Upper limit of Normal(ULN) Units per Liter(U/L) for Alanine aminotransferase(ALT),&gt;=2 times ULN U/L for alkaline phosphatase(ALP), &gt;=2 times ULN U/L for aspartate aminotransferase(AST),&gt;=1.5 times ULN micromoles/L for bilirubin,&lt;2 or &gt;2.75 millimoles/L (mmol/L) for calcium,&lt;3 or &gt;9 mmol/L for glucose,&lt;3 or &gt;5.5 mmol/L for potassium and &lt;130 or &gt;150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected to analyze PCI ranges: &gt;=2 times ULN U/L for Alanine aminotransferase(ALT),&gt;=2 times ULN U/L for alkaline phosphatase(ALP), &gt;=2 times ULN U/L for aspartate aminotransferase(AST),&gt;=1.5 times ULN micromoles/L for bilirubin,&lt;2 or &gt;2.75 mmol/L for calcium,&lt;3 or &gt;9 mmol/L for glucose,&lt;3 or &gt;5.5 mmol/L for potassium and &lt;130 or &gt;150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits.</description>
        <time_frame>Up to 26 days</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose Placebo</title>
            <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected to analyze PCI ranges: &gt;=2 times ULN U/L for Alanine aminotransferase(ALT),&gt;=2 times ULN U/L for alkaline phosphatase(ALP), &gt;=2 times ULN U/L for aspartate aminotransferase(AST),&gt;=1.5 times ULN micromoles/L for bilirubin,&lt;2 or &gt;2.75 mmol/L for calcium,&lt;3 or &gt;9 mmol/L for glucose,&lt;3 or &gt;5.5 mmol/L for potassium and &lt;130 or &gt;150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP: To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin:To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium:To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: To Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: To within Range or No Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: To High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline</title>
        <description>Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose Placebo</title>
            <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline</title>
          <description>Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occult Blood, No change/decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, Increase to positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, No change/decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Increase to positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline</title>
        <description>Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner (proportional concentrations in urine samples), and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein. 'No change/decreased' indicates no change from Baseline results or decreased in results from Baseline including change in negative results. 'Increase to positive' indicates increase in result from Baseline. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.</description>
        <time_frame>Up to 26 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose Placebo</title>
            <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline</title>
          <description>Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner (proportional concentrations in urine samples), and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein. 'No change/decreased' indicates no change from Baseline results or decreased in results from Baseline including change in negative results. 'Increase to positive' indicates increase in result from Baseline. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occult Blood, No change/decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, Increase to positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, No change/decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Increase to trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline</title>
        <description>Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were &lt;85 (Low), 85-160 (Normal) and &gt;160 (High) for SBP; &lt;45 (Low), 45-100 (Normal), &gt;100 (High) for DBP; &lt;40 (Low), 40-110 (Normal), &gt;110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose Placebo</title>
            <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline</title>
          <description>Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were &lt;85 (Low), 85-160 (Normal) and &gt;160 (High) for SBP; &lt;45 (Low), 45-100 (Normal), &gt;100 (High) for DBP; &lt;40 (Low), 40-110 (Normal), &gt;110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline</title>
        <description>Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were &lt;85 (Low), 85-160 (Normal) and &gt;160 (High) for SBP; &lt;45 (Low), 45-100 (Normal), &gt;100 (High) for DBP; &lt;40 (Low), 40-110 (Normal), &gt;110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
        <time_frame>Up to 26 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose Placebo</title>
            <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline</title>
          <description>Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were &lt;85 (Low), 85-160 (Normal) and &gt;160 (High) for SBP; &lt;45 (Low), 45-100 (Normal), &gt;100 (High) for DBP; &lt;40 (Low), 40-110 (Normal), &gt;110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in&quot;To within Range or No Change&quot; category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Results Post Baseline Relative to Baseline</title>
        <description>A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose Placebo</title>
            <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Results Post Baseline Relative to Baseline</title>
          <description>A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal: NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal: CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst Case Abnormal ECG Results Post Baseline Relative to Baseline</title>
        <description>A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
        <time_frame>Up to 26 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose Placebo</title>
            <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Abnormal ECG Results Post Baseline Relative to Baseline</title>
          <description>A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal: NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal: CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose in each treatment period</time_frame>
        <population>PK Population comprised of all participants in the safety population who had at least 1 non-missing PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population comprised of all participants in the safety population who had at least 1 non-missing PK assessment.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1671.7" spread="20.9"/>
                    <measurement group_id="O2" value="6514.1" spread="12.3"/>
                    <measurement group_id="O3" value="17717.9" spread="18.0"/>
                    <measurement group_id="O4" value="28472.2" spread="27.9"/>
                    <measurement group_id="O5" value="21456.4" spread="7.8"/>
                    <measurement group_id="O6" value="48381.2" spread="26.9"/>
                    <measurement group_id="O7" value="65150.2" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-t]) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-t]) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1954.3" spread="24.7"/>
                    <measurement group_id="O2" value="8249.8" spread="18.2"/>
                    <measurement group_id="O3" value="22266.9" spread="16.9"/>
                    <measurement group_id="O4" value="36561.0" spread="26.7"/>
                    <measurement group_id="O5" value="29091.9" spread="10.6"/>
                    <measurement group_id="O6" value="63052.2" spread="26.1"/>
                    <measurement group_id="O7" value="88901.9" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC[0-infinity]) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC[0-infinity]) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2167.0" spread="23.4"/>
                    <measurement group_id="O2" value="8425.5" spread="18.1"/>
                    <measurement group_id="O3" value="22433.7" spread="16.8"/>
                    <measurement group_id="O4" value="36768.0" spread="26.5"/>
                    <measurement group_id="O5" value="29316.1" spread="10.5"/>
                    <measurement group_id="O6" value="63377.3" spread="26.1"/>
                    <measurement group_id="O7" value="89424.5" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.7" spread="22.3"/>
                    <measurement group_id="O2" value="661.7" spread="14.8"/>
                    <measurement group_id="O3" value="1825.8" spread="21.2"/>
                    <measurement group_id="O4" value="3126.7" spread="31.3"/>
                    <measurement group_id="O5" value="1834.5" spread="13.4"/>
                    <measurement group_id="O6" value="4671.3" spread="27.4"/>
                    <measurement group_id="O7" value="5771.6" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.32" spread="29.7"/>
                    <measurement group_id="O2" value="106.70" spread="39.5"/>
                    <measurement group_id="O3" value="283.18" spread="24.7"/>
                    <measurement group_id="O4" value="500.35" spread="28.8"/>
                    <measurement group_id="O5" value="453.82" spread="13.6"/>
                    <measurement group_id="O6" value="853.98" spread="35.0"/>
                    <measurement group_id="O7" value="1291.37" spread="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Time to Cmax (Tmax) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time to Cmax (Tmax) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="2.00" upper_limit="4.18"/>
                    <measurement group_id="O3" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="4.000" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="4.000" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="4.000" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Lag Time for Absorption (Tlag) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Lag Time for Absorption (Tlag) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.375" lower_limit="0.25" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.250" lower_limit="0" upper_limit="0.50"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.250" lower_limit="0" upper_limit="0.25"/>
                    <measurement group_id="O5" value="0.250" lower_limit="0.25" upper_limit="1.50"/>
                    <measurement group_id="O6" value="0.250" lower_limit="0.25" upper_limit="0.50"/>
                    <measurement group_id="O7" value="0.250" lower_limit="0.25" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Terminal Elimination Half-life (T1/2) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Terminal Elimination Half-life (T1/2) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.407" spread="17.7"/>
                    <measurement group_id="O2" value="12.269" spread="14.5"/>
                    <measurement group_id="O3" value="11.538" spread="10.1"/>
                    <measurement group_id="O4" value="12.277" spread="16.0"/>
                    <measurement group_id="O5" value="12.984" spread="10.3"/>
                    <measurement group_id="O6" value="12.630" spread="11.6"/>
                    <measurement group_id="O7" value="12.690" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Area Under the Concentration-time Curve Over the Dosing Interval Tau (AUC[0-tau]) After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve Over the Dosing Interval Tau (AUC[0-tau]) After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5862.9" spread="16.2"/>
                    <measurement group_id="O2" value="20191.4" spread="25.6"/>
                    <measurement group_id="O3" value="45400.0" spread="38.8"/>
                    <measurement group_id="O4" value="53753.9" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6144.9" spread="8.7"/>
                    <measurement group_id="O2" value="21109.5" spread="27.9"/>
                    <measurement group_id="O3" value="61202.0" spread="27.4"/>
                    <measurement group_id="O4" value="82351.1" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Cmax After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Cmax After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.0" spread="20.8"/>
                    <measurement group_id="O2" value="2179.1" spread="29.5"/>
                    <measurement group_id="O3" value="4409.4" spread="34.2"/>
                    <measurement group_id="O4" value="4933.1" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600.4" spread="21.9"/>
                    <measurement group_id="O2" value="2007.4" spread="31.7"/>
                    <measurement group_id="O3" value="5370.3" spread="21.2"/>
                    <measurement group_id="O4" value="6575.2" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Tmax After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Tmax After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.000" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.008" lower_limit="4.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Plasma Concentrations Over the Dosing Interval (Ctau) After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Plasma Concentrations Over the Dosing Interval (Ctau) After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.98" spread="46.8"/>
                    <measurement group_id="O2" value="292.53" spread="22.2"/>
                    <measurement group_id="O3" value="789.85" spread="46.7"/>
                    <measurement group_id="O4" value="1084.55" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.28" spread="26.8"/>
                    <measurement group_id="O2" value="368.34" spread="29.7"/>
                    <measurement group_id="O3" value="1170.62" spread="39.2"/>
                    <measurement group_id="O4" value="1864.47" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Urine Concentration Between 22-24 Hours (C22-24) After Single Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Day 1: 22-24 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Urine Concentration Between 22-24 Hours (C22-24) After Single Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="71.3"/>
                    <measurement group_id="O2" value="2.99" spread="95.9"/>
                    <measurement group_id="O3" value="11.27" spread="146.7"/>
                    <measurement group_id="O4" value="15.26" spread="133.9"/>
                    <measurement group_id="O5" value="11.42" spread="148.0"/>
                    <measurement group_id="O6" value="48.54" spread="161.8"/>
                    <measurement group_id="O7" value="33.50" spread="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Urine Concentration Between 22-24 Hours (C22-24) After Repeat Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Day 1 and Day 7: 22-24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Urine Concentration Between 22-24 Hours (C22-24) After Repeat Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="52.5"/>
                    <measurement group_id="O2" value="11.98" spread="64.8"/>
                    <measurement group_id="O3" value="18.15" spread="42.8"/>
                    <measurement group_id="O4" value="38.43" spread="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="84.4"/>
                    <measurement group_id="O2" value="16.50" spread="26.7"/>
                    <measurement group_id="O3" value="23.60" spread="69.6"/>
                    <measurement group_id="O4" value="57.15" spread="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Single Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Single Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Milligrams</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.16" spread="15.7"/>
                    <measurement group_id="O2" value="32.01" spread="9.4"/>
                    <measurement group_id="O3" value="106.86" spread="25.5"/>
                    <measurement group_id="O4" value="146.43" spread="20.5"/>
                    <measurement group_id="O5" value="95.17" spread="9.2"/>
                    <measurement group_id="O6" value="306.93" spread="20.8"/>
                    <measurement group_id="O7" value="430.03" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Repeat Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Days 1 and 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Repeat Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Milligrams</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.77" spread="17.6"/>
                    <measurement group_id="O2" value="88.30" spread="14.2"/>
                    <measurement group_id="O3" value="188.49" spread="32.5"/>
                    <measurement group_id="O4" value="267.16" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.71" spread="19.0"/>
                    <measurement group_id="O2" value="108.20" spread="17.4"/>
                    <measurement group_id="O3" value="258.08" spread="18.7"/>
                    <measurement group_id="O4" value="390.10" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100 percent (%).</description>
        <time_frame>At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100 percent (%).</description>
          <population>PK Population</population>
          <units>Percent dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.43" spread="15.7"/>
                    <measurement group_id="O2" value="64.02" spread="9.4"/>
                    <measurement group_id="O3" value="71.24" spread="25.5"/>
                    <measurement group_id="O4" value="58.57" spread="20.5"/>
                    <measurement group_id="O5" value="38.07" spread="9.2"/>
                    <measurement group_id="O6" value="61.39" spread="20.8"/>
                    <measurement group_id="O7" value="47.78" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100%.</description>
        <time_frame>Day 1 and Day 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100%.</description>
          <population>PK Population</population>
          <units>Percent dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.54" spread="17.6"/>
                    <measurement group_id="O2" value="58.87" spread="14.2"/>
                    <measurement group_id="O3" value="37.70" spread="32.5"/>
                    <measurement group_id="O4" value="29.68" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.42" spread="19.0"/>
                    <measurement group_id="O2" value="72.13" spread="17.4"/>
                    <measurement group_id="O3" value="51.62" spread="18.7"/>
                    <measurement group_id="O4" value="43.34" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Renal Clearance of Drug (CLr) After Single Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)</description>
        <time_frame>At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Renal Clearance of Drug (CLr) After Single Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)</description>
          <population>PK Population</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="31.7"/>
                    <measurement group_id="O2" value="3.88" spread="25.8"/>
                    <measurement group_id="O3" value="4.80" spread="30.9"/>
                    <measurement group_id="O4" value="4.00" spread="19.1"/>
                    <measurement group_id="O5" value="3.27" spread="14.2"/>
                    <measurement group_id="O6" value="4.87" spread="17.5"/>
                    <measurement group_id="O7" value="4.84" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Renal Clearance of Drug (CLr) After Repeat Dose Administration of GSK3882347</title>
        <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).</description>
        <time_frame>Day 1 and Day 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Renal Clearance of Drug (CLr) After Repeat Dose Administration of GSK3882347</title>
          <description>Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).</description>
          <population>PK Population</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="20.8"/>
                    <measurement group_id="O2" value="4.38" spread="28.6"/>
                    <measurement group_id="O3" value="4.16" spread="28.7"/>
                    <measurement group_id="O4" value="4.98" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="16.9"/>
                    <measurement group_id="O2" value="5.12" spread="19.8"/>
                    <measurement group_id="O3" value="4.22" spread="28.6"/>
                    <measurement group_id="O4" value="4.73" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1181.6" spread="20.3"/>
                    <measurement group_id="O2" value="4609.1" spread="10.2"/>
                    <measurement group_id="O3" value="12519.7" spread="19.7"/>
                    <measurement group_id="O4" value="20127.1" spread="29.1"/>
                    <measurement group_id="O5" value="14009.0" spread="10.1"/>
                    <measurement group_id="O6" value="33030.8" spread="26.8"/>
                    <measurement group_id="O7" value="42353.5" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Plasma Concentrations at 12 Hours (C12) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Plasma Concentrations at 12 Hours (C12) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.73" spread="26.7"/>
                    <measurement group_id="O2" value="232.96" spread="17.1"/>
                    <measurement group_id="O3" value="636.41" spread="18.5"/>
                    <measurement group_id="O4" value="947.62" spread="27.5"/>
                    <measurement group_id="O5" value="857.73" spread="9.5"/>
                    <measurement group_id="O6" value="1806.50" spread="33.9"/>
                    <measurement group_id="O7" value="2714.12" spread="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Apparent Oral Clearance (CL/F) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Oral Clearance (CL/F) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="23.4"/>
                    <measurement group_id="O2" value="5.93" spread="18.1"/>
                    <measurement group_id="O3" value="6.69" spread="16.8"/>
                    <measurement group_id="O4" value="6.80" spread="26.5"/>
                    <measurement group_id="O5" value="8.53" spread="10.5"/>
                    <measurement group_id="O6" value="7.89" spread="26.1"/>
                    <measurement group_id="O7" value="10.06" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Apparent Volume of Distribution After Oral Administration (Vz/F) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Volume of Distribution After Oral Administration (Vz/F) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.92" spread="22.8"/>
                    <measurement group_id="O2" value="105.04" spread="6.7"/>
                    <measurement group_id="O3" value="111.30" spread="22.7"/>
                    <measurement group_id="O4" value="120.43" spread="34.3"/>
                    <measurement group_id="O5" value="159.74" spread="11.3"/>
                    <measurement group_id="O6" value="143.76" spread="30.1"/>
                    <measurement group_id="O7" value="184.26" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Mean Residence Time (MRT) After Single Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 15 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: Single Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Mean Residence Time (MRT) After Single Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.775" lower_limit="12.76" upper_limit="23.46"/>
                    <measurement group_id="O2" value="16.843" lower_limit="12.45" upper_limit="19.61"/>
                    <measurement group_id="O3" value="15.614" lower_limit="13.38" upper_limit="19.62"/>
                    <measurement group_id="O4" value="16.262" lower_limit="14.36" upper_limit="19.84"/>
                    <measurement group_id="O5" value="18.818" lower_limit="16.57" upper_limit="20.73"/>
                    <measurement group_id="O6" value="17.259" lower_limit="15.41" upper_limit="19.89"/>
                    <measurement group_id="O7" value="18.630" lower_limit="15.32" upper_limit="22.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4076.3" spread="16.4"/>
                    <measurement group_id="O2" value="14411.9" spread="28.9"/>
                    <measurement group_id="O3" value="30660.3" spread="37.1"/>
                    <measurement group_id="O4" value="35231.6" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4222.8" spread="11.0"/>
                    <measurement group_id="O2" value="14506.3" spread="28.9"/>
                    <measurement group_id="O3" value="41187.1" spread="24.1"/>
                    <measurement group_id="O4" value="53121.9" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Plasma Concentrations at 12 Hours (C12) After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Plasma Concentrations at 12 Hours (C12) After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.4" spread="23.5"/>
                    <measurement group_id="O2" value="709.1" spread="19.9"/>
                    <measurement group_id="O3" value="1704.8" spread="42.1"/>
                    <measurement group_id="O4" value="2068.2" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.5" spread="11.8"/>
                    <measurement group_id="O2" value="776.1" spread="28.3"/>
                    <measurement group_id="O3" value="2360.8" spread="30.6"/>
                    <measurement group_id="O4" value="3218.5" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using AUC(0-infinity) After Single Dose Administration of GSK3882347 Under Fasted Condition</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. The dose proportionality was assessed for doses administered under fasted conditions only. Being a FTIH study, the impact of food on drug PK was unknown; hence it would have been inaccurate to include fed arm in dose proportionality assessment in this FTIH study. Therefore, 250 mg fed arm was not considered in dose proportionality assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3882347 SD 15 mg to 900 mg</title>
            <description>Healthy participants were administered single dose of GSK3882347 15 mg, 50 mg, 150 mg, 250 mg, 500 mg and 900 mg under fasted condition in either of treatment Period 1, 2, 3 or 4 according to randomization schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using AUC(0-infinity) After Single Dose Administration of GSK3882347 Under Fasted Condition</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. The dose proportionality was assessed for doses administered under fasted conditions only. Being a FTIH study, the impact of food on drug PK was unknown; hence it would have been inaccurate to include fed arm in dose proportionality assessment in this FTIH study. Therefore, 250 mg fed arm was not considered in dose proportionality assessment</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.919" lower_limit="0.889" upper_limit="0.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using Cmax After Single Dose Administration of GSK3882347 Under Fasted Condition</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. The dose proportionality was assessed for doses administered under fasted conditions only. Being a FTIH study, the impact of food on drug PK was unknown; hence it would have been inaccurate to include fed arm in dose proportionality assessment in this FTIH study. Therefore, 250 mg fed arm was not considered in dose proportionality assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3882347 SD 15 mg to 900 mg</title>
            <description>Healthy participants were administered single dose of GSK3882347 15 mg, 50 mg, 150 mg, 250 mg, 500 mg and 900 mg under fasted condition in either of Treatment period 1, 2, 3 or 4 according to randomization schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using Cmax After Single Dose Administration of GSK3882347 Under Fasted Condition</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. The dose proportionality was assessed for doses administered under fasted conditions only. Being a FTIH study, the impact of food on drug PK was unknown; hence it would have been inaccurate to include fed arm in dose proportionality assessment in this FTIH study. Therefore, 250 mg fed arm was not considered in dose proportionality assessment</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.903" lower_limit="0.865" upper_limit="0.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using AUC(0-tau) After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.</description>
        <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3882347 RD 50 mg to 900 mg</title>
            <description>Participants were administered repeat dose of GSK3882347 50 mg, 150 mg, 500 mg or 900 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using AUC(0-tau) After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.770" lower_limit="0.684" upper_limit="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.908" lower_limit="0.841" upper_limit="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using Cmax After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.</description>
        <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3882347 RD 50 mg to 900 mg</title>
            <description>Participants were administered repeat dose of GSK3882347 50 mg, 150 mg, 500 mg or 900 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using Cmax After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.736" lower_limit="0.644" upper_limit="0.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.841" lower_limit="0.763" upper_limit="0.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Observed Accumulation Ratio (Ro) Using AUC(0-tau) After Repeat Dose Administration of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) at Day 7 divided by AUC(0-tau) at Day 1 for GSK3882347. Mixed effect model was used to assess accumulation ratio for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.</description>
        <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Observed Accumulation Ratio (Ro) Using AUC(0-tau) After Repeat Dose Administration of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) at Day 7 divided by AUC(0-tau) at Day 1 for GSK3882347. Mixed effect model was used to assess accumulation ratio for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.</description>
          <population>PK Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.93" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.93" upper_limit="1.18"/>
                    <measurement group_id="O3" value="1.35" lower_limit="1.20" upper_limit="1.52"/>
                    <measurement group_id="O4" value="1.53" lower_limit="1.36" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Time Invariance of GSK3882347</title>
        <description>Blood samples were collected at indicated time points for the analysis of time invariance. Time invariance was calculated as AUC(0-tau) at Day 7 divided by AUC(0-infinity) at Day 1 for GSK3882347. Mixed effect ANOVA model was used to assess time invariance for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.</description>
        <time_frame>Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Time Invariance of GSK3882347</title>
          <description>Blood samples were collected at indicated time points for the analysis of time invariance. Time invariance was calculated as AUC(0-tau) at Day 7 divided by AUC(0-infinity) at Day 1 for GSK3882347. Mixed effect ANOVA model was used to assess time invariance for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.</description>
          <population>PK Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.74" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.77" upper_limit="0.99"/>
                    <measurement group_id="O3" value="1.07" lower_limit="0.95" upper_limit="1.20"/>
                    <measurement group_id="O4" value="1.13" lower_limit="1.00" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Pre-dose Plasma Concentrations After Repeat Dose Administration of GSK3882347 From Days 3 to 7</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347.</description>
        <time_frame>Days 3, 4, 5, 6 and 7: Pre-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
            <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Pre-dose Plasma Concentrations After Repeat Dose Administration of GSK3882347 From Days 3 to 7</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347.</description>
          <population>PK Population</population>
          <units>Nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3: Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.48" spread="19.360"/>
                    <measurement group_id="O2" value="326.89" spread="81.306"/>
                    <measurement group_id="O3" value="1157.589" spread="432.3864"/>
                    <measurement group_id="O4" value="1578.14" spread="328.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4: Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.66" spread="16.722"/>
                    <measurement group_id="O2" value="344.56" spread="112.891"/>
                    <measurement group_id="O3" value="1212.368" spread="438.9076"/>
                    <measurement group_id="O4" value="1883.90" spread="560.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5: Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.16" spread="15.683"/>
                    <measurement group_id="O2" value="329.37" spread="88.100"/>
                    <measurement group_id="O3" value="1166.770" spread="369.9656"/>
                    <measurement group_id="O4" value="1724.07" spread="524.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6: Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.50" spread="21.275"/>
                    <measurement group_id="O2" value="339.83" spread="100.604"/>
                    <measurement group_id="O3" value="1157.068" spread="384.6052"/>
                    <measurement group_id="O4" value="1776.54" spread="513.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.46" spread="14.390"/>
                    <measurement group_id="O2" value="300.16" spread="75.925"/>
                    <measurement group_id="O3" value="1105.470" spread="464.5923"/>
                    <measurement group_id="O4" value="1769.40" spread="618.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28472.2" spread="0.08"/>
                    <measurement group_id="O2" value="21456.4" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Mean</param_type>
            <param_value>0.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Mixed Effect Model has been used to assess Food Effect for the log transformed parameter AUC(0-24). Treatment in the fed/fasted state is fitted as Fixed Effect. Participant is fitted as Random Effect. Unstructured covariance structure is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC [0-t]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC [0-t]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36561.0" spread="0.08"/>
                    <measurement group_id="O2" value="29091.9" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Mean</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Mixed Effect Model was used to assess Food Effect for the log transformed parameter AUC(0-t). Treatment in the fed/fasted state was fitted as Fixed Effect. Participant was fitted as Random Effect. Unstructured covariance structure was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC [0-infinity]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC [0-infinity]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36768.0" spread="0.08"/>
                    <measurement group_id="O2" value="29316.1" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Mean</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Mixed Effect Model was used to assess Food Effect for log transformed parameter AUC(0-infinity). Treatment in the fed/fasted state was fitted as Fixed Effect. Participant was fitted as Random Effect. Unstructured covariance structure was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3126.7" spread="0.10"/>
                    <measurement group_id="O2" value="1834.5" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Mean</param_type>
            <param_value>0.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>Mixed Effect Model was used to assess Food Effect for the log transformed parameter Cmax. Treatment in the fed/fasted state was fitted as Fixed Effect. Participant was fitted as Random Effect. Unstructured covariance structure was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494.7" spread="0.09"/>
                    <measurement group_id="O2" value="449.2" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Mean</param_type>
            <param_value>0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Mixed Effect Model was used to assess Food Effect for the log transformed parameter C24h. Treatment in the fed/fasted state was fitted as Fixed Effect. Participant was fitted as Random Effect. Unstructured covariance structure was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tmax After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tmax After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>2.000</ci_upper_limit>
            <estimate_desc>Wilcoxon matched pair test was used to assess Food Effect for the parameter Tmax.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tlag After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Dose GSK3882347 250 mg</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
            <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tlag After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.250" lower_limit="0.25" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
            <estimate_desc>Wilcoxon matched pair test was used to assess Food Effect for the parameter Tlag.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality, SAEs and Non-SAEs were collected from the start of study treatment up to 3 months for Part 1 and up to 26 days for Part 2</time_frame>
      <desc>All-cause mortality, SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Single Dose Placebo</title>
          <description>Healthy participants in Part 1 received a SD of Placebo on Day 1 in either treatment Periods 1, 2, 3 and 4.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Single Dose GSK3882347 15 mg</title>
          <description>Healthy participants in Part 1 received a SD of GSK3882347 15 mg on Day 1 in treatment Period 3.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Single Dose GSK3882347 50 mg</title>
          <description>Healthy participants in Part 1 received a SD of GSK3882347 50 mg on Day 1 in treatment Period 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Single Dose GSK3882347 150 mg</title>
          <description>Healthy participants in Part 1 received a SD of GSK3882347 150 mg on Day 1 in treatment Period 2.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: Single Dose GSK3882347 250 mg</title>
          <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg on Day 1 in treatment Period 3.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: Single Dose GSK3882347 250 mg Fed</title>
          <description>Healthy participants in Part 1 received a SD of GSK3882347 250 mg under fed condition on Day 1 in treatment Period 4.</description>
        </group>
        <group group_id="E7">
          <title>Part 1: Single Dose GSK3882347 500 mg</title>
          <description>Healthy participants in Part 1 received a SD of GSK3882347 500 mg on Day 1 in treatment Period 1.</description>
        </group>
        <group group_id="E8">
          <title>Part 1: Single Dose GSK3882347 900 mg</title>
          <description>Healthy participants in Part 1 received a SD of GSK3882347 900 mg on Day 1 in treatment Period 2.</description>
        </group>
        <group group_id="E9">
          <title>Part 2: Repeat Dose Placebo</title>
          <description>Healthy participants in Part 2 received repeat dose (RD) of Placebo on Days 1 to 7.</description>
        </group>
        <group group_id="E10">
          <title>Part 2: Repeat Dose GSK3882347 50 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 50 mg on Days 1 to 7.</description>
        </group>
        <group group_id="E11">
          <title>Part 2: Repeat Dose GSK3882347 150 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 150 mg on Days 1 to 7.</description>
        </group>
        <group group_id="E12">
          <title>Part 2: Repeat Dose GSK3882347 500 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 500 mg on Days 1 to 7.</description>
        </group>
        <group group_id="E13">
          <title>Part 2: Repeat Dose GSK3882347 900 mg</title>
          <description>Healthy participants in Part 2 received RD of GSK3882347 900 mg on Days 1 to 7.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Product use complaint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>8664357343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04488770
org study id: 212148
secondary id: 2020-000680-23
nct id: NCT04488770
lead sponsor: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled,
      first time in human (FTIH) study, that includes both single-ascending and multiple-ascending
      dose phase to assess the safety, tolerability, and pharmacokinetics (PK) of GSK3882347 in
      healthy adult men and Woman of Non Childbearing Potential (WONCBP). Part 1 will be the single
      ascending dose (SAD) phase and Part 2 will be the multiple ascending dose (MAD) phase. Each
      participant in the SAD cohort will receive a single dose of GSK3882347 or placebo (PBO) in
      3:1 ratio and in Part 2 (MAD), participants will be randomized in a 4:1 ratio to receive
      active treatment and placebo. Part 1 will consist of two cohorts with a maximum of
      four-period for each cohort, the food effect evaluation will be conducted in last period
      (Period 4) in only one of the cohorts based on the observed human pharmacokinetics (PK). Part
      2 will consist of maximum of four cohorts for each of the MAD dose or placebo.
allocation: Randomized
intervention model: Crossover Assignment
intervention model description: Part 1 will consist of two cohorts (Cohorts 1 and 2) with a maximum of four periods in a cross-over design conducted in two separate cohorts. Part 2 consists of a maximum of four ascending repeat-dose cohorts (Cohorts 3 to 6) for which participants, will receive a single oral dose of GSK3882347 or placebo for 7 days.
primary purpose: Treatment
masking: Double (Participant, Investigator)
masking description: This will be a double-blind study with participants and the site staff blinded.
measure: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
time frame: Up to 3 months
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (greater than or equal to [>=]5 percent [%]) non-serious AEs is presented.
measure: Part 2: Number of Participants With Non-serious AEs and SAEs
time frame: Up to 26 days
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (>=5%) non-serious AEs is presented.
measure: Part 1: Number of Participants With Treatment Related AEs
time frame: Up to 3 months
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.
measure: Part 2: Number of Participants With Treatment Related AEs
time frame: Up to 26 days
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs is presented.
measure: Part 1: Number of Participants With Worst-case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
time frame: Up to 3 months
description: Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were <0.075 or >0.54 proportion of red blood cells in blood for hematocrit, <25 or >180 grams per liter(g/L) for hemoglobin,<3 or >20 x10^9 cells per liter(cells/L) for leukocytes,<0.8 x10^9 cells/L for lymphocytes,<1.5 x10^9 cells/L for neutrophils and <100 or >550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(for example[e.g.],High to High),or whose value became within range, were recorded in"To within Range or No Change" category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits
measure: Part 2: Number of Participants With Worst-case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline
time frame: Up to 26 days
description: Blood samples were collected to analyze hematocrit,hemoglobin,leukocytes,lymphocytes,neutrophils and platelets. PCI ranges were <0.075 or >0.54 proportion of red blood cells in blood for hematocrit, <25 or >180 grams per liter(g/L) for hemoglobin,<3 or >20 x10^9 cells per liter(cells/L) for leukocytes,<0.8 x10^9 cells/L for lymphocytes,<1.5 x10^9 cells/L for neutrophils and <100 or >550 x10^9 cells/L for platelets.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in"To within Range or No Change" category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value, including those from unscheduled visits
measure: Part 1: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline
time frame: Up to 3 months
description: Blood samples were collected to analyze PCI ranges: >=2 times Upper limit of Normal(ULN) Units per Liter(U/L) for Alanine aminotransferase(ALT),>=2 times ULN U/L for alkaline phosphatase(ALP), >=2 times ULN U/L for aspartate aminotransferase(AST),>=1.5 times ULN micromoles/L for bilirubin,<2 or >2.75 millimoles/L (mmol/L) for calcium,<3 or >9 mmol/L for glucose,<3 or >5.5 mmol/L for potassium and <130 or >150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in"To within Range or No Change" category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits
measure: Part 2: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline
time frame: Up to 26 days
description: Blood samples were collected to analyze PCI ranges: >=2 times ULN U/L for Alanine aminotransferase(ALT),>=2 times ULN U/L for alkaline phosphatase(ALP), >=2 times ULN U/L for aspartate aminotransferase(AST),>=1.5 times ULN micromoles/L for bilirubin,<2 or >2.75 mmol/L for calcium,<3 or >9 mmol/L for glucose,<3 or >5.5 mmol/L for potassium and <130 or >150 mmol/L for sodium.Participants were counted in worst case category that their value changes to(low,within range or no change or high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range,were recorded in"To within Range or No Change" category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline=latest pre-dose assessment with a non-missing value,including those from unscheduled visits.
measure: Part 1: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline
time frame: Up to 3 months
description: Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.
measure: Part 2: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline
time frame: Up to 26 days
description: Urine samples were collected for the analysis of urine parameters including occult blood and protein by dipstick. The dipstick test gave results in a semi-quantitative manner (proportional concentrations in urine samples), and results for urinalysis parameters were recorded as no change/decreased, increase to positive for urine occult blood and protein. 'No change/decreased' indicates no change from Baseline results or decreased in results from Baseline including change in negative results. 'Increase to positive' indicates increase in result from Baseline. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with worst case urinalysis results Post Baseline relative to Baseline is presented.
measure: Part 1: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline
time frame: Up to 3 months
description: Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were <85 (Low), 85-160 (Normal) and >160 (High) for SBP; <45 (Low), 45-100 (Normal), >100 (High) for DBP; <40 (Low), 40-110 (Normal), >110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in"To within Range or No Change" category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits
measure: Part 2: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline
time frame: Up to 26 days
description: Vital signs were assessed including Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). PCI ranges were <85 (Low), 85-160 (Normal) and >160 (High) for SBP; <45 (Low), 45-100 (Normal), >100 (High) for DBP; <40 (Low), 40-110 (Normal), >110 (High) for pulse rate. Participants were counted in worst case category that their value changes to(low,within range or no change, high),unless there is no change in their category.Participants whose laboratory value category was unchanged(e.g.,High to High),or whose value became within range, were recorded in"To within Range or No Change" category.Participants were counted twice if the participant has values that changed 'To Low' and 'To High',so the percentages may not add to 100%.Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits
measure: Part 1: Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Results Post Baseline Relative to Baseline
time frame: Up to 3 months
description: A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
measure: Part 2: Number of Participants With Worst Case Abnormal ECG Results Post Baseline Relative to Baseline
time frame: Up to 26 days
description: A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
measure: Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-t]) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC[0-infinity]) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Time to Cmax (Tmax) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Lag Time for Absorption (Tlag) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Terminal Elimination Half-life (T1/2) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Area Under the Concentration-time Curve Over the Dosing Interval Tau (AUC[0-tau]) After Repeat Dose Administration of GSK3882347
time frame: Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Cmax After Repeat Dose Administration of GSK3882347
time frame: Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Tmax After Repeat Dose Administration of GSK3882347
time frame: Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Plasma Concentrations Over the Dosing Interval (Ctau) After Repeat Dose Administration of GSK3882347
time frame: Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Urine Concentration Between 22-24 Hours (C22-24) After Single Dose Administration of GSK3882347
time frame: Day 1: 22-24 hours post-dose in each treatment period
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Urine Concentration Between 22-24 Hours (C22-24) After Repeat Dose Administration of GSK3882347
time frame: Day 1 and Day 7: 22-24 hours post-dose
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Single Dose Administration of GSK3882347
time frame: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Repeat Dose Administration of GSK3882347
time frame: Days 1 and 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347
time frame: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100 percent (%).
measure: Part 2: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347
time frame: Day 1 and Day 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. %fe was calculated as: (Ae total/Dose)*100%.
measure: Part 1: Renal Clearance of Drug (CLr) After Single Dose Administration of GSK3882347
time frame: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24, 24-26, 26-32, 32-38, 38-48, 48-60, 60-72, 72-84, 84-96 hours post-dose in each treatment period
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)
measure: Part 2: Renal Clearance of Drug (CLr) After Repeat Dose Administration of GSK3882347
time frame: Day 1 and Day 7: At 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-22, 22-24 hours post-dose
description: Urine samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).
measure: Part 1: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Plasma Concentrations at 12 Hours (C12) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Apparent Oral Clearance (CL/F) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Apparent Volume of Distribution After Oral Administration (Vz/F) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Mean Residence Time (MRT) After Single Dose Administration of GSK3882347
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Repeat Dose Administration of GSK3882347
time frame: Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2: Plasma Concentrations at 12 Hours (C12) After Repeat Dose Administration of GSK3882347
time frame: Days 1 and 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8 and 12 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using AUC(0-infinity) After Single Dose Administration of GSK3882347 Under Fasted Condition
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.
measure: Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using Cmax After Single Dose Administration of GSK3882347 Under Fasted Condition
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented. The SD 250 mg fed treatment was not considered in the analysis.
measure: Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using AUC(0-tau) After Repeat Dose Administration of GSK3882347
time frame: Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.
measure: Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using Cmax After Repeat Dose Administration of GSK3882347
time frame: Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% CI for the slope are presented.
measure: Part 2: Observed Accumulation Ratio (Ro) Using AUC(0-tau) After Repeat Dose Administration of GSK3882347
time frame: Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) at Day 7 divided by AUC(0-tau) at Day 1 for GSK3882347. Mixed effect model was used to assess accumulation ratio for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.
measure: Part 2: Time Invariance of GSK3882347
time frame: Day 1 and Day 7: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24 hours post-dose
description: Blood samples were collected at indicated time points for the analysis of time invariance. Time invariance was calculated as AUC(0-tau) at Day 7 divided by AUC(0-infinity) at Day 1 for GSK3882347. Mixed effect ANOVA model was used to assess time invariance for the log transformed parameters. Treatment, day and the interaction of treatment and day were fitted as fixed effect. Participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used.
measure: Part 2: Pre-dose Plasma Concentrations After Repeat Dose Administration of GSK3882347 From Days 3 to 7
time frame: Days 3, 4, 5, 6 and 7: Pre-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347.
measure: Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC [0-t]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC [0-infinity]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Tmax After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1: Tlag After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect
time frame: Pre-dose, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 32, 48, 72 and 96 hours post-dose
description: Blood samples were collected at indicated time points for PK analysis of GSK3882347 250 mg under fasted and fed conditions for assessment of food effect. PK parameters were analyzed using standard non-compartmental analysis.
arm group label: Part 1 (SAD) Cohort 1:Participants receiving GSK3882347
arm group type: Experimental
description: In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
arm group label: Part 1 (SAD),Cohort 1:Participants receiving Placebo
arm group type: Placebo Comparator
description: In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
arm group label: Part 1 (SAD),Cohort 2: Participants receiving GSK3882347
arm group type: Experimental
description: In this single ascending dose phase, participants will receive GSK3882347 500 mg, 15 mg and 900 mg orally on Day 1 of period 1, 3 and 2 respectively.
arm group label: Part 1 (SAD),Cohort 2: Participants receiving Placebo
arm group type: Placebo Comparator
description: In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 3 and 2.
arm group label: Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg
arm group type: Experimental
description: In this multiple ascending dose phase, participants will receive GSK3882347 50 mg orally on Day 1 to Day 7 of the study. The dose to be administered may be changed based on clinical safety, tolerability and PK findings in Part 1.
arm group label: Part 2 (MAD),Cohort 3: Participants receiving Placebo
arm group type: Placebo Comparator
description: In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
arm group label: Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg
arm group type: Experimental
description: GSK3882347 150 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
arm group label: Part 2 (MAD),Cohort 4: Participants receiving Placebo
arm group type: Placebo Comparator
description: In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
arm group label: Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg
arm group type: Experimental
description: GSK3882347 500 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
arm group label: Part 2 (MAD),Cohort 5: Participants receiving Placebo
arm group type: Placebo Comparator
description: In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
arm group label: Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg
arm group type: Experimental
description: GSK3882347 900 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 6 will be based on PK/PD results from preceding dosing cohorts.
arm group label: Part 2(MAD),Cohort 6: Participants receiving Placebo
arm group type: Placebo Comparator
description: In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
intervention type: Drug
intervention name: GSK3882347
description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
arm group label: Part 1 (SAD) Cohort 1:Participants receiving GSK3882347
arm group label: Part 1 (SAD),Cohort 2: Participants receiving GSK3882347
arm group label: Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg
arm group label: Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg
arm group label: Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg
arm group label: Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg
intervention type: Drug
intervention name: Placebo
description: Matching strength placebo capsules will be provided
arm group label: Part 1 (SAD),Cohort 1:Participants receiving Placebo
arm group label: Part 1 (SAD),Cohort 2: Participants receiving Placebo
arm group label: Part 2 (MAD),Cohort 3: Participants receiving Placebo
arm group label: Part 2 (MAD),Cohort 4: Participants receiving Placebo
arm group label: Part 2 (MAD),Cohort 5: Participants receiving Placebo
arm group label: Part 2(MAD),Cohort 6: Participants receiving Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Urinary Tract Infections
sharing ipd: Yes
ipd description: IPD for this study will be made available via the Clinical Study Data Request site.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
ipd access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
ipd url: http://clinicalstudydatarequest.com
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 